Copertina

Topical Ruxolitinib for Immune Checkpoint Inhibitor–Induced Vitiligo

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Federico Venturi, Ina Sotiri, Barbara Melotti, Monika Fida, Emi Dika
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2026
Soggetti:	International Journal of Dermatology
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Topical Ruxolitinib as an Effective Therapy for Vitiligo‐Like Lesions Induced by Anti‐ PD ‐1 Therapy
di: Lorenzo Maria Pinto, et al.
Pubblicazione: (2025)

Longitudinal Dermoscopic and LC ‐ OCT Monitoring of Facial Vitiligo Treated With Topical Ruxolitinib: A Pilot Prospective Study
di: Luca Ambrosio, et al.
Pubblicazione: (2026)

Immune Checkpoint Inhibitor–Associated Autoimmune Bullous Diseases: Beyond Bullous Pemphigoid
di: Ioannis‐Alexios Koumprentziotis, et al.
Pubblicazione: (2026)

Effectiveness and Safety of Ruxolitinib Cream 15 mg/g in Patients With Non‐Segmental Vitiligo: A Real‐Life Study
di: Mattia Cristallo, et al.
Pubblicazione: (2025)

Predictors of Response to Topical Ruxolitinib in Non‐segmental Vitiligo: A Narrative Review
di: Luca Bettolini, et al.
Pubblicazione: (2026)

Lichen Planopilaris Induced by Checkpoint Inhibitors: A Systematic Review
di: Niyoosha Yoosefi, et al.
Pubblicazione: (2025)

Erosive Mucocutaneous Eruptions in Patients Treated With Immune Checkpoint Inhibitors: A Case Series
di: Valerie Jaroenpuntaruk, et al.
Pubblicazione: (2026)

Development of Multiple Flat Warts During Treatment With Ruxolitinib 1.5% Cream for Non‐Segmental Vitiligo: A Case Report
di: Veronica Lestani, et al.
Pubblicazione: (2025)

Autoimmune Bullous Diseases Associated With Immune Checkpoint Inhibitors: An Analysis Based on a Systematic Review
di: Min Zou, et al.
Pubblicazione: (2026)

Dermoscopy of Atypical Granular Cell Tumor: Sometimes Yellow Is More Than Expected
di: Martina Lambertini, et al.
Pubblicazione: (2025)

Double Trouble: A Case Series on Dual Morphology Cutaneous Immune‐Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors
di: Joseph Ebriani, et al.
Pubblicazione: (2025)

The Role of Imaging Techniques in Pigmented Bowen Disease and Lentigo Maligna of the Head and Neck: A Comparative Dermoscopic and Reflectance Confocal Microscopy Study
di: Federico Venturi, et al.
Pubblicazione: (2026)

Cytoreductive approach with hedgehog inhibitors followed by reflectance confocal microscopy assisted Mohs surgery for morpheiform basal cell carcinoma
di: Federico Venturi, et al.
Pubblicazione: (2024)

Acral melanoma: Molecular subtyping as a gateway to precision medicine
di: Emi Dika, et al.
Pubblicazione: (2025)

Reply to ‘Risk stratification of cutaneous melanoma using deep learning on whole slide images’
di: Elisabetta Magnaterra, et al.
Pubblicazione: (2025)

Homeopathic Vitiligo Treatments: A Safety Assessment Study
di: Kritin K. Verma, et al.
Pubblicazione: (2026)

Perianal Crohn's Disease Successfully Treated With Topical Ruxolitinib
di: Rebeca Martinez, et al.
Pubblicazione: (2025)

The Impact of Vitiligo on Patients' Quality of Life: Retrospective Observational Study
di: Vincenzo Picone, et al.
Pubblicazione: (2025)

Advancing the Understanding and Management of Segmental Vitiligo and Co‐Existing Pigmentary Disorders
di: Rashmi Sarkar, et al.
Pubblicazione: (2025)

Novel Use of a Topical JAK / STAT Inhibitor in the Management of Refractory Erythromelalgia: A Case Report
di: Alexandra Gershman, et al.
Pubblicazione: (2026)

Successful Treatment of Clear Cell Sarcoma Using Radiotherapy and Immune Checkpoint Inhibitors
di: Kenya Tokai, et al.
Pubblicazione: (2025)

Pathogenesis of Vitiligo: Integrating Immune and Non‐Immune Cell Crosstalk
di: Shintaro Inoue
Pubblicazione: (2025)

Association of Vitiligo With Metabolic and Cardiovascular Comorbidities: A Multicenter Propensity‐Matched Cohort Analysis
di: Kritin K. Verma, et al.
Pubblicazione: (2026)

Vitiligo and psychological stress: A hypothesis integrating the neuroendocrine and immune systems in melanocyte destruction
di: Mohammed S. Al Abadie, et al.
Pubblicazione: (2024)

The Risk of Immune‐Mediated Skin Disease Under Dipeptidyl‐Peptidase IV Inhibitor: A Global Population‐Based Study
di: Noor Mruwat, et al.
Pubblicazione: (2025)

Clinicodemographic Features and Usage of Oral Immunosuppressive Agents in Childhood and Adolescent Vitiligo: Retrospective Chart Review From a Tertiary Care Centre in Northern India
di: Muthu Sendhil Kumaran, et al.
Pubblicazione: (2025)

Topical statins as antifungals: a review
di: Dana M. Khoury, et al.
Pubblicazione: (2024)

Extended‐Interval Dosing of an Immune Checkpoint Inhibitor Following a Complete Response in Melanoma: A Case Report
di: Yoshiyuki Matsui, et al.
Pubblicazione: (2025)

Limited Effectiveness of IL ‐17 Inhibitors for Anti‐ TNF ‐Induced Psoriasis in Hidradenitis Suppurativa: A Multicenter Retrospective Study
di: Leonardo Bascón, et al.
Pubblicazione: (2026)

Dual Immune‐Related Toxicities: Secukinumab‐Induced Bullous Pemphigoid Following ICI ‐Associated Psoriasis in a Cancer Patient
di: Ioanna A. Paschou, et al.
Pubblicazione: (2025)

Pathogenesis of Chemical Leukoderma and Chemical‐Induced Vitiligo
di: Yasutaka Kuroda, et al.
Pubblicazione: (2025)

Topical Sirolimus Treatment of Recurrent Lymphangioma Circumscriptum
di: Eline Vandersteen, et al.
Pubblicazione: (2025)

Acne Lesions Induced by Oral JAK Inhibitors Include Comedones: Insights From Six Patients Without Any Prior History of Acne
di: Sarina Ban, et al.
Pubblicazione: (2026)

Anti‐SAE‐Antibody Positive Dermatomyositis Under Immune Checkpoint Inhibitor Therapy for Hypopharyngeal Cancer: A Case Report
di: Riichiro Sugiura, et al.
Pubblicazione: (2025)

Vulval Lichen Sclerosus Associated With Immune Checkpoint Inhibitor Therapy: A Case Series of 11 Patients
di: Sophie Walter, et al.
Pubblicazione: (2026)

Clinical Outcomes of Dacarbazine After Failure of Immune Checkpoint Inhibitors: A Case Study of 15 Japanese Patients With Malignant Melanoma
di: Ken Horisaki, et al.
Pubblicazione: (2026)

Clinical Features of Nasal and Paranasal Mucosal Melanomas in the Era of Immune Checkpoint Inhibitors: Insights From a Single‐Institution Analysis
di: Yuma Waki, et al.
Pubblicazione: (2026)

RAF ‐Kinase Inhibitor Associated Hair Hypopigmentation
di: Elizabeth Botto, et al.
Pubblicazione: (2026)

Efficacy and Safety of Phosphodiesterase‐4 Inhibitors in Vitiligo: A Systematic Review
di: Reya Hanspal, et al.
Pubblicazione: (2025)

Use of Oral JAK Inhibitors and a TYK2 Inhibitor in the Treatment of Psoriasis–Eczema Overlap ( PsEma ): A Retrospective Study
di: Marley Cutrona, et al.
Pubblicazione: (2026)